Fig. 9: Systemic nanoparticle delivery of diABZI potentiates the anti-glioma effects of radiotherapy.

C57 mice received intracranial implantation of 7.5×10⁴ CT-2A cells and three administrations of saline, free diABZI, or P-LNP/diABZI (2.5 mg/kg diABZI) through intravenous injections. Selected groups of mice received radiotherapy (RT, 3 Gy×3) as monotherapy or combination therapy. a Survival curves of CT-2A-bearing C57 mice received different treatments. n = 6–7 mice per group. Survival curves were compared using Log-rank test for those with proportional hazards or Renyi’s test for those with crossing hazards with p values adjusted by Bonferroni correction. b 180 d after tumor implantation, long-term survivor (LTS) mice were rechallenged with 7.5×10⁴ CT-2A cells in the opposite hemisphere of the initial tumor injection site. The animal survival was compared to age-matched tumor-bearing control mice (NT). c Tumor burden in control and LTS mice were evaluated through H&E staining. Scale bar, 2.5 mm; insert scale bar, 1 mm. d 100 d post-rechallenge, freshly dissected brains from LTS, age-matched tumor-bearing mice, and age-matched non-tumor control mice were analyzed by flow cytometry for immune composition and CD8⁺ T cell phenotypes. n = 5 mice. Statistics were determined by two-sided Student’s t-test. The data are presented as mean + /- SEM. Source data are provided as a Source Data file.